Dr. Wachter is a physician-scientist combining compassionate, leading-edge care of children with high-risk myeloid malignancies with innovative research in experimental therapeutics. She earned her M.D. from Ludwig Maximilian University in Munich, Germany, graduating summa cum laude from Irmela Jeremia’s laboratory, where she explored mechanisms of chemoresistance and p53 reactivation in response to the extrinsic apoptotic pathway agonist TRAIL. Dr. Wachter began her postdoctoral training in Loren Walensky’s lab at Dana-Farber Cancer Institute, where she focused on interrogating BCL-2 family protein biology through the lens of chemical biology. She completed her pediatric residency and pediatric oncology fellowship at Boston Children’s Hospital, followed by postdoctoral training in Eric Fischer’s lab, where she honed her expertise in structural biology. Her research program is focused on using modern structural biology with the goal to target aberrant transcription in myeloid malignancies. Clinically, Dr. Wachter specializes in pediatric stem cell transplantation, with a focus on difficult-to-treat myeloid leukemias. Her clinical research is dedicated to the role of novel therapeutics in controlling disease before and after hematopoietic stem cell transplantation, including leading a trial on decitabine-enhanced graft versus leukemia effect.